- NetworkNewsWire Editorial Coverage
NEW YORK, March 6, 2020 /PRNewswire/ -- Product offerings focused on enhancing mental health and wellness are broadening as companies that are committed to helping consumers are looking for a variety of ways — both natural and prescription-based — to offer support, support that includes an array of new functional foods and medicines.
Canadian company Champignon Brands Inc. (CSE: SHRM) (Profile) is one of the first to provide such natural products as it sets out to expand its product line, including offering products containing mushrooms, which have been proven effective in the mental health and wellness space. Another company focused on natural health solutions is Herbalife Nutrition Ltd. (NYSE: HLF), a global nutrition company. Going with more traditional mental health options, Axsome Therapeutics (NASDAQ: AXSM) recently reported favorable results for its late-stage, experimental depression treatment, which showed significant improvements in patients with major depressive disorder. BioXcel Therapeutics Inc. (NASDAQ: BTAI) focuses on utilizing cutting-edge technology and innovative research to develop its high-value therapeutics aimed at transforming patients' lives. And with colleagues and commercial operations in an estimated 100 countries, Allergan (NYSE: AGN) is committed to working with physicians, healthcare providers and patients to deliver innovative treatments that help people around the world live longer, healthier lives.
To view an infographic of this editorial, click here.
Make Room for Mushrooms
With the legalization of medical cannabis in many jurisdictions, regulators and businesses are looking at other natural drugs that might be legally available for consumers. Mushrooms, with their powerful ability to affect brain chemistry, looks set to become the next major legalization drive in America.
A wide range of companies and investors alike are moving to make the most of this space. Like the mushrooms themselves, new companies are springing up out of fertile ground. These companies aim to provide customers with the health benefits that mushrooms can bring, while providing investors with opportunities in this nascent market.
The 'Shroom Boom
Among these companies is Champignon Brands Inc. (CSE: SHRM), one of the only public companies focused entirely on a mushroom-to-market strategy. Champignon currently offers consumer packaged goods (CPGs) in the form of teas that capitalize on the use of functional mushrooms and provide an opportunity for entry-level exposure to the burgeoning boom in mushroom products.
Champignon is committed to cultivating and distributing artisanal medical mushrooms and the CPGs derived from those mushrooms. As a legal market, this is new territory, and Champignon is a young company. The company recently successfully completed its initial public offering of more than 18 million common shares at a price of $0.15 per share for total gross proceeds of more than $2.8 million. The company's common shares were listed on the Canadian Securities Exchange beginning February 27, 2020. After a brief halt pending IPO completion, the common shares resumed trading under the symbol SHRM on March 2, 2020. In addition, Champignon working to secure listings in the United States and Germany as it seeks to create a strong presence in both North America and Europe.
This deliberate approach looks to be a smart strategy for this emerging presence in the functional mushroom sector. Laying the global groundwork now should position Champignon to make the most of the high-profile American market while also reaching other high-value, health-conscious consumers around the world.
Naturally Occuring New Medicine
Psilocybin is at the core of the work Champignon is doing. A naturally occurring chemical, psilocybin can be found in hundreds of types of mushrooms, providing the fungi with their psychedelic qualities. While the power of psilocybin has been recognized for decades, its medical potential is now being fully researched.
This mushroom momentum is driven by growing acceptance from medical professionals and institutions. Thomas Insel, former director of the U.S. National Institute of Mental Health, and Paul Summergrad, former head of the American Psychiatric Association, are both on the board of advisers for Compass Pathways, a leading psilocybin company. Johns Hopkins, one of America's most prestigious research universities, has established a new psychedelic research center focused on examining the potential of such chemicals, largely funded through the efforts of angel investor Tim Ferriss.
Ferriss isn't the only high-profile investor to have taken an interest in the tasty fungi. Bruce Linton and Kevin O'Leary are seed investors in MindMed, while Peter Thiel has invested in Compass Pathways. Wild as it might seem to outsiders, Champignon is working in a field with growing scientific and financial credibility.
The market available to companies such as Champignon has long been limited by laws restricting the use and sale of psilocybin mushrooms and their derivatives. Now those laws are starting to change.
Denver, Oakland, and most recently Santa Cruz are among the places that have already decriminalized psilocybin. Some of the same people who championed those changes are now involved in wider efforts, with campaigns for decriminalization in areas such as Oregon and Iowa. In November 2019, Decriminalize California teamed up with the Beckley Foundation to replicate the success of decriminalization in Oakland throughout the state of California. Vermont, Michigan and Washington have also commenced movements toward legalization.
The case for legalizing shrooms isn't the same as for cannabis. While some of the same arguments about health benefits and personal choice are fielded, psilocybin legalization doesn't involve the huge potential tax benefits or the massive implications for the criminal justice system. Companies such as Champignon aren't looking to tap into the same huge painkilling market as THC and CBD products. Instead, these companies occupy a significant niche focusing on supporting mental health, where it is believed that psilocybin could create new treatments and potentially radically improve the lives of sufferers.
Support for legalization isn't clearly divided along party lines. Peter Thiel is a Trump ally while a recent attempt to make research easier was pushed by radical Democrat Alexandria Ocasio-Cortez. Like hemp farming, this is an industry with potential to reach across the political divide.
Building a Strategy Around Medicine
As psilocybin legalization grows, so has research research and development. Studies are looking at how to refine and synthesize the chemical as well as how to integrate it into product development. The R&D element is a essential part of Champignon's strategy.
Any company developing products within the health and wellness sector needs a medicinal IP strategy in order to provide the unique products and medical advances that make a medical company stand out — both to customers and investors. Champignon's plan is to use laboratory experiments to develop a way of biosynthesizing psilocybin, with the aim of reaching this milestone marker within the first three months of experiments. This would allow optimized and scaled production of pharmaceutical grade psilocybin.
With efficient, large-scale production, the company will be able to deploy its products in clinical settings, thus staking a serious claim in the medical market.
Psilocybin products have value not just in the clinical space but also in the retail one. Functional foods and beverages are growing in popularity thanks to cannabis and CBD, and psilocybin provides an opportunity to diversify this $200 billion sector with new and distinctive products.
Functional foods and drinks such as Champignon's Vitality Superteas and its upcoming mushroom-infused cold brew coffee are a natural entry point for psilocybin into this sector. Both of these one-of-a-kind product offerings will reach a broader market and raise awareness of mushrooms' emerging potential. Champignon plans to use a mix of national brick-and-mortar distribution, e-commerce and online influencer marketing to raise the profile of its products and build a strong, loyal customer base.
The Business of Health and Wellness
Mental health and wellness is a lucrative industry, with many companies committed to offer a range of products designed to help consumers live better lives.
Herbalife Nutrition Ltd. (NYSE: HLF) offers products that, when combined with a balanced diet and exercise, provide consumers with a comprehensive and personalized solution to their nutrition and wellness goals. Herbalife products include protein shakes and bars, teas, aloe, vitamins and sports hydration products, all backed by science and designed to meet customers' diverse needs.
Axsome Therapeutics Inc. (NASDAQ: AXSM) develops and commercializes differentiated medicines that expand the treatment options available to caregivers and improve the lives of patients living with CNS disorders. Most recently, the company reported favorable results for its late-stage, experimental depression treatment, which showed significant improvements in patients with major depressive disorder (MDD) (http://nnw.fm/k1GuF).
BioXcel Therapeutics Inc. (NASDAQ: BTAI) is a clinical-stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology. BTAI employs a unique AI platform in an effort to reduce therapeutic development costs and potentially accelerate timelines, while aiming to increase the possibility of success.
Allergan plc (NYSE: AGN) is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products. The company is committed to a social contract that "begins where there is a patient with an unmet need. As we identify needs in our areas of expertise in the U.S. and around the world, we are committed to risking billions of dollars to develop life-enhancing innovations."
With legalization spreading and a wide range of companies dedicated to enhancing the mental health and well-being of those in need around the world, the use of mushrooms certainly seems to have a place in the space.
For more information about Champignon Brands Inc., please visit Champignon Brands Inc. (CSE: SHRM).
NetworkNewsWire ("NNW") is a financial news and content distribution company, one of 40+ brands within the InvestorBrandNetwork ("IBN"), that provides: (1) access to a network of wire solutions via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text "STOCKS" to 77948 (U.S. Mobile Phones Only)
For more information, please visit: https://www.NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with NNW or any company mentioned herein. The commentary, views and opinions expressed in this release by NNW are solely those of NNW and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW and FNM for any investment decisions by their readers or subscribers. NNW and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment.
NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW and FNM undertake no obligation to update such statements.
Corporate Communications Contact:
FN Media Group, LLC